These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 9289276)

  • 1. [Tularemia vaccine strain is a potential vector].
    Pavlov VM; Mokrievich AN; Noskov AN; Urakov NN
    Vestn Ross Akad Med Nauk; 1997; (6):30-2. PubMed ID: 9289276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virulence determinants and protective antigens of Francisella tularensis.
    Sjöstedt A
    Curr Opin Microbiol; 2003 Feb; 6(1):66-71. PubMed ID: 12615222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized Type A F. tularensis.
    Jia Q; Lee BY; Clemens DL; Bowen RA; Horwitz MA
    Vaccine; 2009 Feb; 27(8):1216-29. PubMed ID: 19126421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deletion of IglH in virulent Francisella tularensis subsp. holarctica FSC200 strain results in attenuation and provides protection against the challenge with the parental strain.
    Straskova A; Cerveny L; Spidlova P; Dankova V; Belcic D; Santic M; Stulik J
    Microbes Infect; 2012 Feb; 14(2):177-87. PubMed ID: 21930232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective immunity against tularemia provided by an adenovirus-vectored vaccine expressing Tul4 of Francisella tularensis.
    Kaur R; Chen S; Arévalo MT; Xu Q; Chen Y; Zeng M
    Clin Vaccine Immunol; 2012 Mar; 19(3):359-64. PubMed ID: 22278325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationally designed tularemia vaccines.
    Mann BJ; Ark NM
    Expert Rev Vaccines; 2009 Jul; 8(7):877-85. PubMed ID: 19538114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Francisella tularensis--a model for studies of the immune response to intracellular bacteria in man.
    Tärnvik A; Eriksson M; Sandström G; Sjöstedt A
    Immunology; 1992 Jul; 76(3):349-54. PubMed ID: 1526645
    [No Abstract]   [Full Text] [Related]  

  • 8. Nature of protective immunity to Francisella tularensis.
    Tärnvik A
    Rev Infect Dis; 1989; 11(3):440-51. PubMed ID: 2665002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccines against Francisella tularensis.
    Wayne Conlan J; Oyston PC
    Ann N Y Acad Sci; 2007 Jun; 1105():325-50. PubMed ID: 17395730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlates of protection following vaccination of mice with gene deletion mutants of Francisella tularensis subspecies tularensis strain, SCHU S4 that elicit varying degrees of immunity to systemic and respiratory challenge with wild-type bacteria.
    Ryden P; Twine S; Shen H; Harris G; Chen W; Sjostedt A; Conlan W
    Mol Immunol; 2013 May; 54(1):58-67. PubMed ID: 23201853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [CONSTRUCTION AND PROPERTIES OF THE FRANCISELLA TULARENSIS VACCINE STRAIN WITHOUT ONE COPY OF THE IGLC GENE AND WITHOUT RECA GENE].
    Mokrievich AN; Vakhrameeva GM; Titareva GM; Bakhteeva IV; Mironova RI; Kombarova TI; Kravchenko TB; Dyatlov IA; Pavlov VM
    Mol Gen Mikrobiol Virusol; 2015; 33(3):33-9. PubMed ID: 26665740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination strategies for Francisella tularensis.
    Isherwood KE; Titball RW; Davies DH; Felgner PL; Morrow WJ
    Adv Drug Deliv Rev; 2005 Jun; 57(9):1403-14. PubMed ID: 15919131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of immunobiological activity of Francisella tularensis C-complex preparations as promising component of subunit vaccines].
    Volokh OA; Shepelev IA; Firsova VV; Khramkova EM; Avdeeva NG; Samokhvalova IuI; Eremin SA; Diatlov IA; Zhemchugov VE
    Zh Mikrobiol Epidemiol Immunobiol; 2007; (3):16-21. PubMed ID: 17672125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccines against Francisella tularensis--past, present and future.
    Conlan JW
    Expert Rev Vaccines; 2004 Jun; 3(3):307-14. PubMed ID: 15176947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress, challenges, and opportunities in Francisella vaccine development.
    Elkins KL; Kurtz SL; De Pascalis R
    Expert Rev Vaccines; 2016 Sep; 15(9):1183-96. PubMed ID: 27010448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tularemia vaccines.
    Putzova D; Senitkova I; Stulik J
    Folia Microbiol (Praha); 2016 Nov; 61(6):495-504. PubMed ID: 27194547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Francisella tularensis subspecies novicida purF mutant, but not a purA mutant, induces protective immunity to tularemia in mice.
    Quarry JE; Isherwood KE; Michell SL; Diaper H; Titball RW; Oyston PC
    Vaccine; 2007 Mar; 25(11):2011-8. PubMed ID: 17241711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Live attenuated tularemia vaccines: recent developments and future goals.
    Marohn ME; Barry EM
    Vaccine; 2013 Aug; 31(35):3485-91. PubMed ID: 23764535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dominance of human innate immune responses in primary Francisella tularensis live vaccine strain vaccination.
    Fuller CL; Brittingham KC; Hepburn MJ; Martin JW; Petitt PL; Pittman PR; Bavari S
    J Allergy Clin Immunol; 2006 May; 117(5):1186-8. PubMed ID: 16675351
    [No Abstract]   [Full Text] [Related]  

  • 20. A glucan-particle based tularemia subunit vaccine induces T-cell immunity and affords partial protection in an inhalation rat infection model.
    Whelan AO; Flick-Smith HC; Walker NJ; Abraham A; Levitz SM; Ostroff GR; Oyston PCF
    PLoS One; 2024; 19(5):e0294998. PubMed ID: 38713688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.